Generics - Biotechnology, Research

Filter

Current filters:

BiotechnologyResearch

Popular Filters

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Phase III data support biosimilarity of BOW-015 to Remicade

29-08-2013

Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Hospira's biosimilar epoetin meets primary endpoints in post-marketing study

04-06-2013

Leading provider of injectable drugs and infusion technologies Hospira (NYSE: HSP) says that results…

BiotechnologyepoetinGenericsOncologyResearchRetacrit

Pfenex and Agila Biotech set up JV to develop biosimilars

16-04-2013

US biotech firm Pfenex Inc. and Agila Biotech, a subsidiary of Indian drugmaker Strides Arcolab (BO:…

Agila BiotechBayerBetaferonBetaseronBiotechnologyGenericsGlobalNeurologicalPfenexProductionResearchStrides Arcolab

Support for introduction of a global regulatory process for biosimilars

16-04-2013

The majority of surveyed US and European physicians and payers are in favor of the introduction of a…

BiotechnologyGenericsGlobalRegulationResearch

US FY 2014 budget continues push to curb patent settlements, shorten biologics exclusivity; a lawyer's view

12-04-2013

At first look, the US Food and Drug Administration appears to have fared rather well under President…

BiotechnologyGenericsNorth AmericaPatentsPoliticsRegulationResearch

Both biosimilar and reference biologics companies must consider product-specific and regional strategies

09-04-2013

With sales forecasted to exceed $16.8 billion by 2021, manufacturers competing in the biosimilars market…

BiotechnologyGenericsMarkets & MarketingPatentsProductionResearch

Indian Pharma growth outpaces rivals, but must embrace innovation

12-03-2013

Ranking among the top five globally by production volume, the Indian pharmaceutical market at present…

Asia-PacificBiotechnologyGenericsMarkets & MarketingPharmaceuticalProductionResearch

Catalent and UMN Pharma collaborate for biosimilars development and production in Japan

16-12-2012

Privately-held USA-based Catalent Pharma Solutions and Japanese drugmaker UMN Pharma (TYO Mothers: 4585)…

Asia-PacificBiotechnologyCatalent Pharma SolutionsGenericsProductionResearchUMN PharmaVaccines

AET BioTech and BioXpress to co-develop biosimilar Humira

02-11-2012

Plans to develop another biosimilar version of Abbott Laboratories blockbuster rheumatoid arthritis drug…

Abbott LaboratoriesadalimumabAET BioTechAnti-Arthritics/RheumaticsBiotechnologyBioXpress TherapeuticsGenericsHumiraProductionResearch

EMA expects lower rate of generic applications; Issues guidelines on schizophrenia and MS

11-10-2012

In its mid-year report for 2012, the European Medicines Agency's management board yesterday provided…

BiotechnologyEuropeGenericsNeurologicalPharmaceuticalRegulationResearch

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

Kyowa Hakko sets up biosimilars joint venture with Fujifilm

29-03-2012

Japanese digital camera and medical equipment conglomerate Fujifilm and drugmaker Kyowa Hakko Kirin have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyFujifilm Kyowa Kirin BiologicsGenericsHumiraKyowa Hakko KirinMergers & AcquisitionsResearch

Future for biosimilars hugely promising, Momenta CEO tells GPhA meeting

26-02-2012

Craig Wheeler, chief executive of Momenta Pharmaceuticals (Nasdaq: MNTA) discussed the promise and prospects…

BiotechnologyGenericsMarkets & MarketingMomenta PharmaceuticalsResearch

Back to top